{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T12:23:39Z","timestamp":1790166219112,"version":"4.1.0"},"reference-count":45,"publisher":"Impact Journals, LLC","issue":"17","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Oncotarget"],"published-print":{"date-parts":[[2016,4,26]]},"DOI":"10.18632\/oncotarget.8332","type":"journal-article","created":{"date-parts":[[2016,3,24]],"date-time":"2016-03-24T13:47:03Z","timestamp":1458827223000},"page":"24436-24454","source":"Crossref","is-referenced-by-count":16,"title":["BM microenvironmental protection of CML cells from imatinib through Stat5\/NF-\u03baB signaling and reversal by Wogonin"],"prefix":"10.18632","volume":"7","author":[{"given":"Xuefen","family":"Xu","sequence":"first","affiliation":[{"name":"State Key Laboratory of Natural Medicines, Jiangsu Key Laboratory of Drug Design and Optimization, China Pharmaceutical University, Nanjing 210009, People's Republic of China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaobo","family":"Zhang","sequence":"additional","affiliation":[{"name":"State Key Laboratory of Natural Medicines, Jiangsu Key Laboratory of Drug Design and Optimization, China Pharmaceutical University, Nanjing 210009, People's Republic of China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yicheng","family":"Liu","sequence":"additional","affiliation":[{"name":"State Key Laboratory of Natural Medicines, Jiangsu Key Laboratory of Drug Design and Optimization, China Pharmaceutical University, Nanjing 210009, People's Republic of China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lin","family":"Yang","sequence":"additional","affiliation":[{"name":"State Key Laboratory of Natural Medicines, Jiangsu Key Laboratory of Drug Design and Optimization, China Pharmaceutical University, Nanjing 210009, People's Republic of China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shaoliang","family":"Huang","sequence":"additional","affiliation":[{"name":"State Key Laboratory of Natural Medicines, Jiangsu Key Laboratory of Drug Design and Optimization, China Pharmaceutical University, Nanjing 210009, People's Republic of China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lu","family":"Lu","sequence":"additional","affiliation":[{"name":"State Key Laboratory of Natural Medicines, Jiangsu Key Laboratory of Drug Design and Optimization, China Pharmaceutical University, Nanjing 210009, People's Republic of China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shuhao","family":"Wang","sequence":"additional","affiliation":[{"name":"Middle School of The City, Mei County, Baoji, Shaanxi 721000, People's Republic of China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qinglong","family":"Guo","sequence":"additional","affiliation":[{"name":"State Key Laboratory of Natural Medicines, Jiangsu Key Laboratory of Drug Design and Optimization, China Pharmaceutical University, Nanjing 210009, People's Republic of China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Li","family":"Zhao","sequence":"additional","affiliation":[{"name":"State Key Laboratory of Natural Medicines, Jiangsu Key Laboratory of Drug Design and Optimization, China Pharmaceutical University, Nanjing 210009, People's Republic of China"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"7892","published-online":{"date-parts":[[2016,3,24]]},"reference":[{"key":"1","doi-asserted-by":"crossref","first-page":"2408","DOI":"10.1056\/NEJMoa062867","article-title":"Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia","volume":"355","author":"Powell","year":"2006","journal-title":"N Engl J Med"},{"key":"2","doi-asserted-by":"crossref","first-page":"1029","DOI":"10.1016\/S1470-2045(10)70233-3","article-title":"Discontinuation of imatinib in patients with chronic myeloid leukaemia who have maintained complete molecular remission for at least 2 years: the prospective, multicentre Stop Imatinib (STIM) trial","volume":"11","author":"Rousselot","year":"2010","journal-title":"Lancet Oncol"},{"key":"3","doi-asserted-by":"crossref","first-page":"4532","DOI":"10.1182\/blood-2005-07-2947","article-title":"Dasatinib (BMS-354825) targets an earlier progenitor population than imatinib in primary CML but does not eliminate the quiescent fraction","volume":"107","author":"Holyoake","year":"2006","journal-title":"Blood"},{"key":"4","doi-asserted-by":"crossref","first-page":"2093","DOI":"10.1182\/blood-2004-03-1114","article-title":"Detection of BCR-ABL kinase mutations in CD34+ cells from chronic myelogenous leukemia patients in complete cytogenetic remission on imatinib mesylate treatment","volume":"105","author":"Bhatia","year":"2005","journal-title":"Blood"},{"key":"5","doi-asserted-by":"crossref","first-page":"1370","DOI":"10.1182\/blood-2006-02-003145","article-title":"Functional ABCG2 is overexpressed on primary CML CD34+ cells and is inhibited by imatinib mesylate","volume":"108","author":"Mountford","year":"2006","journal-title":"Blood"},{"key":"6","doi-asserted-by":"crossref","first-page":"1150","DOI":"10.1182\/blood-2009-01-202606","article-title":"The leukemic stem cell niche: current concepts and therapeutic opportunities","volume":"114","author":"Gilliland","year":"2009","journal-title":"Blood"},{"key":"7","doi-asserted-by":"crossref","first-page":"1532","DOI":"10.1182\/blood.V98.5.1532","article-title":"Adhesion to fibronectin selectively protects Bcr-Abl+ cells from DNA damage-induced apoptosis","volume":"98","author":"Aulitzky","year":"2001","journal-title":"Blood"},{"key":"8","doi-asserted-by":"crossref","first-page":"1189","DOI":"10.1038\/sj.leu.2404667","article-title":"Increased resistance to a farnesyltransferase inhibitor by N-cadherin expression in Bcr\/Abl-P190 lymphoblastic leukemia cells","volume":"21","author":"Heisterkamp","year":"2007","journal-title":"Leukemia"},{"key":"9","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1111\/j.1365-2141.2006.06435.x","article-title":"Beta1 integrin mediated adhesion increases Bim protein degradation and contributes to drug resistance in leukaemia cells","volume":"136","author":"Dalton","year":"2007","journal-title":"Br J Haematol"},{"key":"10","doi-asserted-by":"crossref","first-page":"1140","DOI":"10.1038\/leu.2011.325","article-title":"Blockade of JAK2-mediated extrinsic survival signals restores sensitivity of CML cells to ABL inhibitors","volume":"26","author":"Deininger","year":"2012","journal-title":"Leukemia"},{"key":"11","doi-asserted-by":"crossref","first-page":"4917","DOI":"10.1182\/blood-2005-10-4110","article-title":"STAT5 signaling is required for the efficient induction and maintenance of CML in mice","volume":"107","author":"Ilaria","year":"2006","journal-title":"Blood"},{"key":"12","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1002\/emmm.201000062","article-title":"Stat5 is indispensable for the maintenance of bcr\/abl-positive leukaemia","volume":"2","author":"Beug","year":"2010","journal-title":"EMBO Mol Med"},{"key":"13","doi-asserted-by":"crossref","first-page":"10058","DOI":"10.1128\/MCB.24.22.10058-10071.2004","article-title":"FoxO3a and BCR-ABL regulate cyclin D2 transcription through a STAT5\/BCL6-dependent mechanism","volume":"24","author":"Lam","year":"2004","journal-title":"Mol Cell Biol"},{"key":"14","doi-asserted-by":"crossref","first-page":"6188","DOI":"10.1038\/sj.onc.1204834","article-title":"Involvement of Jak2 tyrosine phosphorylation in Bcr-Abl transformation","volume":"20","author":"Arlinghaus","year":"2001","journal-title":"Oncogene"},{"key":"15","doi-asserted-by":"crossref","first-page":"3409","DOI":"10.1182\/blood-2009-10-248211","article-title":"High STAT5 levels mediate imatinib resistance and indicate disease progression in chronic myeloid leukemia","volume":"117","author":"Egger","year":"2011","journal-title":"Blood"},{"key":"16","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1002\/emmm.201000062","article-title":"Stat5 is indispensable for the maintenance of bcr\/abl-positive leukaemia","volume":"2","author":"Beug","year":"2010","journal-title":"EMBO Mol Med"},{"key":"17","doi-asserted-by":"crossref","first-page":"1669","DOI":"10.1038\/onc.2009.7","article-title":"Jak2 inhibition deactivates Lyn kinase through the SET-PP2A-SHP1 pathway, causing apoptosis in drug-resistant cells from chronic myelogenous leukemia patients","volume":"28","author":"Arlinghaus","year":"2009","journal-title":"Oncogene"},{"key":"18","doi-asserted-by":"crossref","first-page":"2147","DOI":"10.1182\/blood-2006-08-040022","article-title":"Adaptive secretion of granulocyte-macrophage colony-stimulating factor (GM-CSF) mediates imatinib and nilotinib resistance in BCR\/ABL+ progenitors via JAK-2\/STAT-5 pathway activation","volume":"109","author":"Burchert","year":"2007","journal-title":"Blood"},{"key":"19","doi-asserted-by":"crossref","first-page":"12804","DOI":"10.1073\/pnas.96.22.12804","article-title":"Autocrine production and action of IL-3 and granulocyte colony-stimulating factor in chronic myeloid leukemia","volume":"96","author":"Eaves","year":"1999","journal-title":"Proc Natl Acad Sci U S A"},{"key":"20","doi-asserted-by":"crossref","first-page":"1225","DOI":"10.1182\/blood.V92.4.1225","article-title":"Bcl-3 expression and nuclear translocation are induced by granulocyte-macrophage colony-stimulating factor and erythropoietin in proliferating human erythroid precursors","volume":"92","author":"Miller","year":"1998","journal-title":"Blood"},{"key":"21","doi-asserted-by":"crossref","first-page":"8081","DOI":"10.1073\/pnas.95.14.8081","article-title":"Evidence for a role of NF-kappaB in the survival of hematopoietic cells mediated by interleukin 3 and the oncogenic TEL\/platelet-derived growth factor receptor beta fusion protein","volume":"95","author":"Bourgeade","year":"1998","journal-title":"Proc Natl Acad Sci U S A"},{"key":"22","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1186\/1476-4598-8-67","article-title":"STAT5 regulation of BCL10 parallels constitutive NFkappaB activation in lymphoid tumor cells","volume":"8","author":"Kirken","year":"2009","journal-title":"Mol Cancer"},{"key":"23","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1126\/science.275.5299.523","article-title":"Regulation of NF-kappaB by cyclin-dependent kinases associated with the p300 coactivator","volume":"275","author":"Nabel","year":"1997","journal-title":"Science"},{"key":"24","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1111\/j.1527-3458.2005.tb00266.x","article-title":"Therapeutic potential of wogonin: a naturally occurring flavonoid","volume":"11","author":"Xue","year":"2005","journal-title":"Cns Drug Rev"},{"key":"25","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1016\/S0006-2952(01)00876-0","article-title":"Wogonin and fisetin induce apoptosis in human promyeloleukemic cells, accompanied by a decrease of reactive oxygen species, and activation of caspase 3 and Ca (2+)-dependent endonuclease","volume":"63","author":"Chen","year":"2002","journal-title":"Biochem Pharmacol"},{"key":"26","doi-asserted-by":"crossref","first-page":"E81","DOI":"10.1002\/mc.22182","article-title":"Wogonin suppresses human alveolar adenocarcinoma cell A549 migration in inflammatory microenvironment by modulating the IL-6\/STAT3 signaling pathway","volume":"54","author":"Lu","year":"2015","journal-title":"Mol Carcinog"},{"key":"27","doi-asserted-by":"crossref","first-page":"e106458","DOI":"10.1371\/journal.pone.0106458","article-title":"Wogonin suppresses melanoma cell B16-F10 invasion and migration by inhibiting Ras-medicated pathways","volume":"9","author":"Lu","year":"2014","journal-title":"PLoS One"},{"key":"28","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1016\/j.taap.2013.04.031","article-title":"Wogonin inhibits tumor angiogenesis via degradation of HIF-1alpha protein","volume":"271","author":"Guo","year":"2013","journal-title":"Toxicol Appl Pharmacol"},{"key":"29","doi-asserted-by":"crossref","first-page":"956","DOI":"10.1016\/j.lfs.2008.02.013","article-title":"Wogonin suppresses tumor growthand VEGF-induced angiogenesis through inhibiting tyrosine phosphorylation of VEGFR2","volume":"82","author":"Guo","year":"2008","journal-title":"Life Sci"},{"key":"30","doi-asserted-by":"crossref","first-page":"689","DOI":"10.1111\/j.1349-7006.2008.00728.x","article-title":"Wogonin induces the granulocytic differentiation of human NB4 promyelocytic leukemia cells and up-regulates phospholipid scramblase 1 gene expression","volume":"99","author":"Wang","year":"2008","journal-title":"Cancer Sci"},{"key":"31","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1111\/j.1749-6632.2009.04722.x","article-title":"Inhibition of P-glycoprotein by wogonin is involved with the potentiation of etoposide-induced apoptosis in cancer cells","volume":"1171","author":"Hirano","year":"2009","journal-title":"Ann N Y Acad Sci"},{"key":"32","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1002\/mc.20789","article-title":"Oroxylin A reverses multi-drug resistance of human hepatoma BEL7402\/5-FU cells via downregulation of P-glycoprotein expression by inhibiting NF-kappaB signaling pathway","volume":"51","author":"Guo","year":"2012","journal-title":"Mol Carcinog"},{"key":"33","doi-asserted-by":"crossref","first-page":"824","DOI":"10.1002\/mc.21921","article-title":"Drug resistance associates with activation of Nrf2 in MCF-7\/DOX cells, and wogonin reverses it by down-regulating Nrf2-mediated cellular defense response","volume":"52","author":"Hu","year":"2013","journal-title":"Mol Carcinog"},{"key":"34","doi-asserted-by":"crossref","first-page":"997","DOI":"10.1182\/blood.V85.4.997.bloodjournal854997","article-title":"Functionally distinct human marrow stromal cell lines immortalized by transduction with the human papilloma virus E6\/E7 genes","volume":"85","author":"Torok-Storb","year":"1995","journal-title":"Blood"},{"key":"35","doi-asserted-by":"crossref","first-page":"2531","DOI":"10.1056\/NEJMoa055229","article-title":"Dasatinib in imatinib-resistant Philadelphia chromosome-positive leukemias","volume":"354","author":"Chen","year":"2006","journal-title":"N Engl J Med"},{"key":"36","doi-asserted-by":"crossref","first-page":"2542","DOI":"10.1056\/NEJMoa055104","article-title":"Nilotinib in imatinib-resistant CML and Philadelphia chromosome-positive ALL","volume":"354","author":"Griffin","year":"2006","journal-title":"N Engl J Med"},{"key":"37","doi-asserted-by":"crossref","first-page":"9624","DOI":"10.1158\/0008-5472.CAN-08-1131","article-title":"Effects of dasatinib on SRC kinase activity and downstream intracellular signaling in primitive chronic myelogenous leukemia hematopoietic cells","volume":"68","author":"Bhatia","year":"2008","journal-title":"Cancer Res"},{"key":"38","doi-asserted-by":"crossref","first-page":"2218","DOI":"10.4049\/jimmunol.166.4.2218","article-title":"NF-kappa B\/Rel participation in the lymphokine-dependent proliferation of T lymphoid cells","volume":"166","author":"Boothby","year":"2001","journal-title":"J Immunol"},{"key":"39","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1016\/j.ccr.2009.02.015","article-title":"Persistently activated Stat3 maintains constitutive NF-kappaB activity in tumors","volume":"15","author":"Yu","year":"2009","journal-title":"Cancer Cell"},{"key":"40","doi-asserted-by":"crossref","first-page":"6254","DOI":"10.1074\/jbc.M109878200","article-title":"Cytokine receptor common beta subunit-mediated STAT5 activation confers NF-kappa B activation in murine proB cell line Ba\/F3 cells","volume":"277","author":"Tanaka","year":"2002","journal-title":"J Biol Chem"},{"key":"41","doi-asserted-by":"crossref","first-page":"1757","DOI":"10.2174\/156802610792928103","article-title":"Reversal of multidrug resitance by natural substances from plants","volume":"10","author":"Wang","year":"2010","journal-title":"Curr Top Med Chem"},{"key":"42","first-page":"2843","article-title":"Effect of magnetic nanoparticles of Fe3O4 and wogonin on the reversal of multidrug resistance in K562\/A02 cell line","volume":"7","author":"Wang","year":"2012","journal-title":"Int J Nanomedicine"},{"key":"43","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1016\/j.phymed.2009.06.005","article-title":"Wogonin, an active compound in Scutellaria baicalensis, induces apoptosis and reduces telomerase activity in the HL-60 leukemia cells","volume":"17","author":"Pang","year":"2010","journal-title":"Phytomedicine"},{"key":"44","doi-asserted-by":"publisher","first-page":"8188","DOI":"10.18632\/oncotarget.2340","article-title":"Wogonin induces cell cycle arrest and erythroid differentiation in imatinib-resistant K562 cells and primary CML cells","volume":"5","author":"Lu","year":"2014","journal-title":"Oncotarget"},{"key":"45","first-page":"789","article-title":"Effect of magnetic nanoparticles on apoptosis and cell cycle induced by wogonin in Raji cells","volume":"7","author":"Cai","year":"2012","journal-title":"Int J Nanomedicine"}],"container-title":["Oncotarget"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.oncotarget.com\/lookup\/doi\/10.18632\/oncotarget.8332","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,6,15]],"date-time":"2024-06-15T08:11:36Z","timestamp":1718439096000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.oncotarget.com\/lookup\/doi\/10.18632\/oncotarget.8332"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,3,24]]},"references-count":45,"journal-issue":{"issue":"17","published-print":{"date-parts":[[2016,4,26]]}},"alternative-id":["8332","27027438"],"URL":"https:\/\/doi.org\/10.18632\/oncotarget.8332","relation":{},"ISSN":["1949-2553"],"issn-type":[{"value":"1949-2553","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,3,24]]}}}